Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Norway study: routine endometrial cancer screening "inadvisable"

This article was originally published in Clinica

Executive Summary

Despite an incidence of 500 cases of endometrial cancer in Norway each year, there is no evidence to suggest that mass screening would reduce this figure, says Helga Salvesen, from the gynaecological clinic at Haukeland Hospital in Bergen. In an article published this month in the Journal of the Norwegian Doctors' Association (Tidsskr Nor Laegeforen 2002; 122: 1767), Dr Salvesen conceded that the relatively high incidence, the possibility of effective, early-stage treatment of the disease, combined with the fact that the endometrial mucus membrane is easily accessible for examination, do indicate that screening could be beneficial. "[However] the quality of available methods is too low for a person to be declared either apparently healthy or ill with a reasonable degree of accuracy in a mass screening of the population," she added.

You may also be interested in...



Butterfly Network’s CEO Sees Blank Check Deal As Path To ‘Democratize’ Portable Imaging Platform

Butterfly Network chose SPAC route with Longview Acquisition Corp. to scale its business and expand into the home market in 2021.

Regenerative Medicine Comes Of Age – In The Age Of COVID-19

Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.

With Warp Speed Decisions Already Made, Transitioning To Biden Admin Should Be No Trouble, Slaoui Says

As vaccines near availability, Moncef Slaoui says his full-time role at OWS may be ending. He has not met with the Biden Transition team, but notes that other Warp Speed officials have.

Topics

UsernamePublicRestriction

Register

OM004559

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel